2022
Transitions of Care in Cystic Fibrosis
DeFilippo E, Talwalkar J, Harris Z, Butcher J, Nasr S. Transitions of Care in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 757-771. PMID: 36344079, DOI: 10.1016/j.ccm.2022.06.016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis
Talwalkar JS, Koff JL, Lee HB, Britto CJ, Mulenos AM, Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. Journal Of The Academy Of Consultation-Liaison Psychiatry 2017, 58: 343-354. PMID: 28576305, DOI: 10.1016/j.psym.2017.04.001.Peer-Reviewed Original ResearchConceptsCFTR modulator therapyCystic fibrosisModulator therapyNovel therapiesCF transmembrane regulatorCFTR modulatorsCentral nervous system functionNovel CF therapiesManagement of depressionWorse medical outcomesMental health specialistsDrug-drug interactionsNervous system functionMental health variablesTreatment guidelinesClinical outcomesMedication interactionsCF centersComorbid depressionCF RegistryAnxiety screeningCF teamNovel agentsHigh riskMedical outcomes
2016
The Approach to Pseudomonas aeruginosa in Cystic Fibrosis
Talwalkar JS, Murray TS. The Approach to Pseudomonas aeruginosa in Cystic Fibrosis. Clinics In Chest Medicine 2016, 37: 69-81. PMID: 26857769, DOI: 10.1016/j.ccm.2015.10.004.BooksMeSH KeywordsAnti-Bacterial AgentsChronic DiseaseCystic FibrosisGlobal HealthHumansMorbidityPseudomonas aeruginosaPseudomonas InfectionsConceptsCystic fibrosisAcute pulmonary exacerbationsDuration of administrationSpecific patient characteristicsStandard of careSite of carePseudomonas aeruginosaPulmonary exacerbationsAntipseudomonal antibioticsPatient characteristicsTreatment optionsEpidemiologic linkChronic infectionHigh prevalenceTreatment decisionsNew vaccinesEarly identificationAggressive useFibrosisAntibiotic selectionInfectionCareLaboratory methodsAeruginosaExacerbation
2009
Diabetes Mellitus and Bone Disease in Cystic Fibrosis
Curran D, McArdle J, Talwalkar J. Diabetes Mellitus and Bone Disease in Cystic Fibrosis. Seminars In Respiratory And Critical Care Medicine 2009, 30: 514-530. PMID: 19760539, DOI: 10.1055/s-0029-1238910.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBone Demineralization, PathologicBone DiseasesCystic FibrosisDiabetes MellitusGlucoseHumansInsulinPancreasConceptsDiabetes mellitusBone diseaseCystic fibrosisBone demineralizationCystic fibrosis-related diabetes mellitusCystic fibrosis-related diabetesType 2 diabetes mellitusType 2 diabetesLower body weightForms of diabetesHepatic glucose productionCystic fibrosis patientsGonadal dysfunctionPulmonary healthGlycemic excursionsChronic inflammationClinical entityLung diseaseInsulin sensitivityPancreatic insufficiencyMetabolic effectsIntestinal absorptionBody weightFibrosis patientsMellitus
2007
Macrolides in Cystic Fibrosis
McArdle JR, Talwalkar JS. Macrolides in Cystic Fibrosis. Clinics In Chest Medicine 2007, 28: 347-360. PMID: 17467553, DOI: 10.1016/j.ccm.2007.02.005.BooksMeSH KeywordsAnti-Bacterial AgentsClinical Trials as TopicCystic FibrosisHumansMacrolidesRespiratory Function TestsConceptsCystic fibrosisChronic pulmonary diseaseDevelopment of bronchiectasisMajority of patientsProgressive lung diseasePositive therapeutic effectHost inflammatory responseAirway surface liquidChronic infection resultsAzithromycin administrationDiffuse panbronchiolitisPulmonary diseaseClinical benefitLung diseaseMucociliary clearanceInflammatory responseTherapeutic effectInfection resultsTissue damageViscous secretionsPatientsSurface liquidDiseaseFibrosisMacrolide antibiotics